Comparative Pharmacology
Head-to-head clinical analysis: DEPO SUBQ PROVERA 104 versus KIRSTY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO SUBQ PROVERA 104 versus KIRSTY.
DEPO-SUBQ PROVERA 104 vs KIRSTY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, thereby inhibiting ovulation and causing endometrial thinning.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the central nervous system, potentiating serotonergic activity.
104 mg subcutaneously every 3 months (13 weeks). Administer into the anterior thigh or abdomen by a healthcare professional.
Not established; no approved dosing available.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours (range 20-80 hours) with chronic administration due to slow absorption from the depot; clinically, this allows for once-weekly dosing.
12.4 ± 3.1 hours in healthy adults; prolonged in hepatic impairment (24–36 hours) and in elderly (15–20 hours).
Primarily metabolized in the liver; metabolites are excreted in urine (70-80%) and feces (20-30%). Less than 1% unchanged in urine.
Primarily hepatic metabolism to inactive metabolites; 5% excreted renally unchanged; 95% eliminated in feces via biliary secretion.
Category C
Category C
Progestin-Only Contraceptive
Progestin-Only Contraceptive